Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562685652> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2562685652 endingPage "e11088" @default.
- W2562685652 startingPage "e11088" @default.
- W2562685652 abstract "e11088 Background: The third-generation nonsteroidal aromatase inhibitors(AIs) are increasingly used as adjuvant and first-line advanced therapy for postmenopausal, hormone receptor-positive breast cancer. Because many patients subsequently experience progress or relapse, it is important to identify agents with efficacy after AI failure. This study is in order to understand efficacy and safety of exemestane and medroxyprogesterone for the advanced breast cancer after AI failure. Methods: Evaluation of exemestane versus medroxyprogesterone study is a randomized, controlled phase II clinical trial in postmenopausal women with HR+ advanced breast cancer (ABC) progressing or recurring after nonsteriodal AI. The primary end point was progress free survial (PFS). Exemestane 25mg orally was administered once daily and medroxyprogesterone 1000mg orally once daily. Results: A total of 40 women were randomly assigned to exemestane (n=20) or medroxyprogesterone (n=20). Approximately 60% of patients had received at least two prior endocrine therapies. Median PFS was 6 months in exemestane group and 3 months in medroxyprogesterone group (P= 0.790). Overall response rate (0 vs 15%) and clinical benefit rate (30% vs 35%, P= 0.736) was similar between exemestane and medroxyprogesterone respectively. Both treatments were well tolerated. There are 6 patients who have grade 1 and grade 2 weight gain in medroxyprogesterone group. There are 2 patients who experienced grade 2 blood sugar increasement. Conclusions: Exemestane and medroxyprogesterone can be used as the treatment choices in a meaningful proportion of postmenopausal women with ABC who have experienced progression or recurrence during treatment with a nonsteriodal AI. We need to carry on the phase III clinical trial to prove the efficacy and safety of the two drugs." @default.
- W2562685652 created "2017-01-06" @default.
- W2562685652 creator A5008763447 @default.
- W2562685652 creator A5009359631 @default.
- W2562685652 creator A5022426865 @default.
- W2562685652 creator A5062811342 @default.
- W2562685652 creator A5067320455 @default.
- W2562685652 date "2011-05-20" @default.
- W2562685652 modified "2023-09-27" @default.
- W2562685652 title "Randomized, controlled phase II trial of exemestane compared with medroxyprogesterone after nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer." @default.
- W2562685652 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.e11088" @default.
- W2562685652 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28023145" @default.
- W2562685652 hasPublicationYear "2011" @default.
- W2562685652 type Work @default.
- W2562685652 sameAs 2562685652 @default.
- W2562685652 citedByCount "0" @default.
- W2562685652 crossrefType "journal-article" @default.
- W2562685652 hasAuthorship W2562685652A5008763447 @default.
- W2562685652 hasAuthorship W2562685652A5009359631 @default.
- W2562685652 hasAuthorship W2562685652A5022426865 @default.
- W2562685652 hasAuthorship W2562685652A5062811342 @default.
- W2562685652 hasAuthorship W2562685652A5067320455 @default.
- W2562685652 hasConcept C121608353 @default.
- W2562685652 hasConcept C126322002 @default.
- W2562685652 hasConcept C143998085 @default.
- W2562685652 hasConcept C168563851 @default.
- W2562685652 hasConcept C2775860665 @default.
- W2562685652 hasConcept C2775930923 @default.
- W2562685652 hasConcept C2775934596 @default.
- W2562685652 hasConcept C2776166826 @default.
- W2562685652 hasConcept C2776306185 @default.
- W2562685652 hasConcept C2778504769 @default.
- W2562685652 hasConcept C29456083 @default.
- W2562685652 hasConcept C530470458 @default.
- W2562685652 hasConcept C71315377 @default.
- W2562685652 hasConcept C71924100 @default.
- W2562685652 hasConceptScore W2562685652C121608353 @default.
- W2562685652 hasConceptScore W2562685652C126322002 @default.
- W2562685652 hasConceptScore W2562685652C143998085 @default.
- W2562685652 hasConceptScore W2562685652C168563851 @default.
- W2562685652 hasConceptScore W2562685652C2775860665 @default.
- W2562685652 hasConceptScore W2562685652C2775930923 @default.
- W2562685652 hasConceptScore W2562685652C2775934596 @default.
- W2562685652 hasConceptScore W2562685652C2776166826 @default.
- W2562685652 hasConceptScore W2562685652C2776306185 @default.
- W2562685652 hasConceptScore W2562685652C2778504769 @default.
- W2562685652 hasConceptScore W2562685652C29456083 @default.
- W2562685652 hasConceptScore W2562685652C530470458 @default.
- W2562685652 hasConceptScore W2562685652C71315377 @default.
- W2562685652 hasConceptScore W2562685652C71924100 @default.
- W2562685652 hasIssue "15_suppl" @default.
- W2562685652 hasLocation W25626856521 @default.
- W2562685652 hasOpenAccess W2562685652 @default.
- W2562685652 hasPrimaryLocation W25626856521 @default.
- W2562685652 hasRelatedWork W1966100371 @default.
- W2562685652 hasRelatedWork W1980928711 @default.
- W2562685652 hasRelatedWork W1984996181 @default.
- W2562685652 hasRelatedWork W2020627042 @default.
- W2562685652 hasRelatedWork W2034320788 @default.
- W2562685652 hasRelatedWork W2084025059 @default.
- W2562685652 hasRelatedWork W2088064703 @default.
- W2562685652 hasRelatedWork W2239310755 @default.
- W2562685652 hasRelatedWork W2941264805 @default.
- W2562685652 hasRelatedWork W3202689974 @default.
- W2562685652 hasVolume "29" @default.
- W2562685652 isParatext "false" @default.
- W2562685652 isRetracted "false" @default.
- W2562685652 magId "2562685652" @default.
- W2562685652 workType "article" @default.